Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, Germany

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-02-01 DOI:10.1016/j.clgc.2024.102289

Madeleine J. Karpinski MSc , Kevin Claassen PhD , Lennart Möller MSc , Johannes Hüsing PhD , Hiltraud Kajüter MSc , Wolfgang P. Fendler MD , Boris Hadaschik MD , Andreas Stang MD

{"title":"Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, Germany","authors":"Madeleine J. Karpinski MSc , Kevin Claassen PhD , Lennart Möller MSc , Johannes Hüsing PhD , Hiltraud Kajüter MSc , Wolfgang P. Fendler MD , Boris Hadaschik MD , Andreas Stang MD","doi":"10.1016/j.clgc.2024.102289","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>There is no organized prostate cancer screening in Germany. The aim of this study was to investigate the development of incidence and survival in patients with primary malignant tumors of the prostate in relation to changing recommendations of prostate-specific antigen (PSA) screening in guidelines.</div></div><div><h3>Methods</h3><div>Age-standardized incidence rates and 5-year relative survival (RS) (period approach) were calculated using data from the cancer registry North Rhine-Westphalia with the subset of the administrative district Münster respectively for the years 1992-2019. Analyses were stratified according to TNM classification.</div></div><div><h3>Results</h3><div>Until 2008 overall prostate cancer incidence increased, followed by a decrease up to 2017 and another increase thereafter. The same trend was observed in nonmetastatic but not in metastatic prostate cancer. Overall 5-year RS showed an increase of 10 percentage points up to period 2005-2009, followed by a constant RS. 5-year RS of patients with distant metastases remained constant from period 2000-2004 to 2015-2019, while 5-year RS with nonmetastatic prostate cancer and lymph node metastases increased slightly.</div></div><div><h3>Discussion</h3><div>Overall and nonmetastatic incidence rates reflect changes of recommendation in PSA screening guidelines from the United States. Accordingly, the increase in 5-year RS might be influenced by lead time bias. Incidence and survival of metastatic prostate cancer barely suggest any association with changing PSA screening recommendations.</div></div><div><h3>Conclusion</h3><div>Structured early detection of metastases with additionally applied diagnostic methods might improve 5-year RS rates of metastatic prostate cancer patients.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 1","pages":"Article 102289"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324002593","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

There is no organized prostate cancer screening in Germany. The aim of this study was to investigate the development of incidence and survival in patients with primary malignant tumors of the prostate in relation to changing recommendations of prostate-specific antigen (PSA) screening in guidelines.

Methods

Age-standardized incidence rates and 5-year relative survival (RS) (period approach) were calculated using data from the cancer registry North Rhine-Westphalia with the subset of the administrative district Münster respectively for the years 1992-2019. Analyses were stratified according to TNM classification.

Results

Until 2008 overall prostate cancer incidence increased, followed by a decrease up to 2017 and another increase thereafter. The same trend was observed in nonmetastatic but not in metastatic prostate cancer. Overall 5-year RS showed an increase of 10 percentage points up to period 2005-2009, followed by a constant RS. 5-year RS of patients with distant metastases remained constant from period 2000-2004 to 2015-2019, while 5-year RS with nonmetastatic prostate cancer and lymph node metastases increased slightly.

Discussion

Overall and nonmetastatic incidence rates reflect changes of recommendation in PSA screening guidelines from the United States. Accordingly, the increase in 5-year RS might be influenced by lead time bias. Incidence and survival of metastatic prostate cancer barely suggest any association with changing PSA screening recommendations.

Conclusion

Structured early detection of metastases with additionally applied diagnostic methods might improve 5-year RS rates of metastatic prostate cancer patients.

查看原文本刊更多论文

德国北莱茵-威斯特伐利亚州前列腺癌患者的发病率和生存率

在德国没有有组织的前列腺癌筛查。本研究的目的是调查原发性前列腺恶性肿瘤患者发病率和生存率的发展与指南中前列腺特异性抗原（PSA）筛查建议的变化之间的关系。方法：使用北莱茵-威斯特伐利亚州癌症登记处1992-2019年m nster行政区子集的数据计算年龄标准化发病率和5年相对生存率（RS）（期法）。根据TNM分类对分析进行分层。结果：到2008年，前列腺癌的总体发病率上升，随后下降到2017年，此后再次上升。在非转移性前列腺癌中观察到同样的趋势，但在转移性前列腺癌中没有。总体5年生存率在2005-2009年期间增加了10个百分点，随后RS保持不变。2000-2004年至2015-2019年期间，远处转移患者的5年生存率保持不变，而非转移性前列腺癌和淋巴结转移患者的5年生存率略有增加。讨论：总体和非转移性发病率反映了美国PSA筛查指南推荐的变化。因此，5年RS的增加可能受到提前期偏差的影响。转移性前列腺癌的发病率和生存率几乎与PSA筛查建议的改变没有任何关联。结论：有组织的早期发现转移并结合其他诊断方法可提高转移性前列腺癌患者5年RS率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.